In an effort to force reductions in prescription drug prices, the Trump administration risks sending those prices through the roof.

Thankfully, the Department of Health and Human Services late last month delayed the expected finalization of a new rule that would radically upend the pharmaceutical market for Medicare Part D. Good. Sometimes it is better, as the criminal Fagin sang in “Oliver,” to “think [we]’d better think it out again.”